Show simple item record

dc.contributor.authorCourtney, A.
dc.contributor.authorO'Connell, R.
dc.contributor.authorRattay, T.
dc.contributor.authorKim, B.
dc.contributor.authorCutress, R. I.
dc.contributor.authorKirwan, C. C.
dc.contributor.authorGandhi, Ashu
dc.contributor.authorFairbrother, P.
dc.contributor.authorSharma, N.
dc.contributor.authorCartlidge, C. W. J.
dc.contributor.authorHorgan, K.
dc.contributor.authorMcIntosh, S. A.
dc.contributor.authorLeff, D. R.
dc.contributor.authorVidya, R.
dc.contributor.authorPotter, S.
dc.contributor.authorHolcombe, C.
dc.contributor.authorCopson, E.
dc.contributor.authorColes, C. E.
dc.contributor.authorDave, R. V.
dc.date.accessioned2020-09-16T11:57:54Z
dc.date.available2020-09-16T11:57:54Z
dc.date.issued2020en
dc.identifier.citationCourtney A, O'Connell R, Rattay T, Kim B, Cutress RI, Kirwan CC, et al. The B-MaP-C study: Breast cancer management pathways during the COVID-19 pandemic. Study protocol. Int J Surg Protoc. 2020;24:1-5.en
dc.identifier.pmid32838092en
dc.identifier.doi10.1016/j.isjp.2020.07.003en
dc.identifier.urihttp://hdl.handle.net/10541/623237
dc.description.abstractIntroduction: Approximately 55,000 women in the United Kingdom are diagnosed with new breast cancer annually. Since emerging in December 2019, SARS-CoV-2 (coronavirus disease 2019, COVID-19) has become a global pandemic, affecting healthcare delivery worldwide. In response to the pandemic, multiple guidelines were issued to assist with rationalising breast cancer care. The primary aim of the B-MaP-C study is to audit and describe breast cancer management of patients newly diagnosed with breast cancer during the COVID-19 pandemic against pre-COVID-19 management practice in the UK. The implications of changes to management will be determined and the impact of a COVID-19 diagnosis on the patient's breast cancer management will be determined. Methods and analysis: This is a multi-centre collaborative audit of consecutive breast cancer patients undergoing treatment decisions during the acute and recovery phases of the COVID-19 pandemic. All patients with newly diagnosed primary breast cancer, whose treatment was decided in a multidisciplinary meeting from the 16th March 2020, are eligible for inclusion. Ethics and dissemination: As this is an audit ethical approval is not required. Each participating centre is required to register the study locally and obtain local governance approvals prior to commencement of data collection. Local audit data will be available to individual participating units for governance purposes. The results of the data analysis will be submitted for publication, as well as disseminated via the ABS newsletter and a webinar. All data will be presented at national and international conferences, circumstances permitting. Registration details: Each participating centre received local governance audit registration.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.isjp.2020.07.003en
dc.titleThe B-MaP-C study: Breast cancer management pathways during the COVID-19 pandemic. Study protocolen
dc.typeArticleen
dc.contributor.departmentDepartment of Surgery and Cancer, Imperial College London, UK.en
dc.identifier.journalInternational Journal of Surgery Protocolsen
dc.description.noteen]
refterms.dateFOA2020-09-16T13:38:29Z


Files in this item

Thumbnail
Name:
IJSurgProt.pdf
Size:
357.4Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record